2025 India Biosimilar Contract Manufacturing Market Revenue Opportunities Report
Description
The 2025 India Biosimilar Contract Manufacturing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biosimilar Contract Manufacturing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biosimilar contract manufacturing market in India are Biocon Biologics, Pfizer, Celltrion Healthcare, and Viatris (formerly Mylan). Biocon Biologics is a leading Indian player with advanced manufacturing facilities, focusing on oncology and immunology biosimilars, leveraging global regulatory approvals and partnerships to scale production. Pfizer aggressively expands its presence through strategic partnerships with local firms, delivering biosimilars in oncology and inflammation therapeutics with products like Bevacizumab and Trastuzumab. Celltrion Healthcare targets autoimmune and oncology biosimilars, utilizing direct supply models for faster market entry. Viatris, in cooperation with Biocon, co-develops and exports biosimilars such as Trastuzumab and Insulin Aspart, holding a significant share in the Indian market.
These companies benefit from India's cost-effective manufacturing capabilities, skilled workforce, and government encouragement for foreign-indigenous partnerships, enhancing India's position as a biosimilar contract manufacturing hub globally. Their portfolios cover critical therapeutic areas including oncology, diabetes, immunology, and autoimmune diseases, driving significant growth in the Indian biosimilar market valued at over USD 866 million in 2024 with a CAGR forecast of 17.38% through 2033.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biosimilar Contract Manufacturing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biosimilar contract manufacturing market in India are Biocon Biologics, Pfizer, Celltrion Healthcare, and Viatris (formerly Mylan). Biocon Biologics is a leading Indian player with advanced manufacturing facilities, focusing on oncology and immunology biosimilars, leveraging global regulatory approvals and partnerships to scale production. Pfizer aggressively expands its presence through strategic partnerships with local firms, delivering biosimilars in oncology and inflammation therapeutics with products like Bevacizumab and Trastuzumab. Celltrion Healthcare targets autoimmune and oncology biosimilars, utilizing direct supply models for faster market entry. Viatris, in cooperation with Biocon, co-develops and exports biosimilars such as Trastuzumab and Insulin Aspart, holding a significant share in the Indian market.
These companies benefit from India's cost-effective manufacturing capabilities, skilled workforce, and government encouragement for foreign-indigenous partnerships, enhancing India's position as a biosimilar contract manufacturing hub globally. Their portfolios cover critical therapeutic areas including oncology, diabetes, immunology, and autoimmune diseases, driving significant growth in the Indian biosimilar market valued at over USD 866 million in 2024 with a CAGR forecast of 17.38% through 2033.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
